Breast cancer prevention: Present and future

Cancer Treatment Reviews

Volumn 27, Issue 5, 2001, Pages 261-273

  Salih, A K ^a   Fentiman, I S ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Genetic susceptibility tamoxifen; Prevention; Raloxifene; Risk factors

Indexed keywords

ALCOHOL; ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; ESTROGEN RECEPTOR; GEFITINIB; GENISTEIN; GONADORELIN; GONADORELIN DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HORMONE; LETRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULINDAC SULFONE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AGING; ALCOHOL CONSUMPTION; BODY FAT; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CASE MIX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DENSITY; DIABETES MELLITUS; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EDEMA; ENDOMETRIUM CANCER; EXERCISE; FEMALE; GENETIC SUSCEPTIBILITY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLUENZA; LACTATION; LEG CRAMP; LIFESPAN; LIFESTYLE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; MENSTRUAL IRREGULARITY; NAUSEA; OBESITY; OSTEOPOROSIS; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 0035187504     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2001.0235     Document Type: Article

References (125)

1. Estimates of the world wide mortality from 25 cancers in 1990
2. The contribution of inherited predisposition to cancer incidence
3. Breast and ovarian cancer incidence in BRCA1 mutation carriers
4. Future possibilities in the prevention of breast cancer. Role of genetic variation in breast cancer prevention
5. Elevated serum estradiol and testosterone concentrations are associated with a high risk of breast cancer
6. Mammographic patterns as a prediction biomarker of breast cancer risk: Effect of tamoxifen
7. Circulating concentrations of insulin-like growth factor-1 and the risk of breast cancer
8. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
9. Projecting individualised probabilities of developing breast cancer for white female who are being examined annually
10. Breast cancer prevention with tamoxifen
11. The prevention of breast cancer
12. Tamoxifen and contralateral breast cancer
13. Adjuvant tamoxifen in early breast cancer. Occurrence of new primary cancers
14. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
15. Tamoxifen for early breast cancer: An overview of the randomised trials
16. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
17. Cardiac and thromboembolic morbidity among postmenopausal women with early breast cancer in a randomised trial of adjuvant tamoxifen
18. Health related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study
19. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
20. Prevention of breast cancer with tamoxifen: Preliminary finding from the Italian randomised trial among hysterectomised women
21. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
22. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from MORE randomised trial
23. Bone density of normal women in relation to endogenous and exogenous estrogens
24. Bone mineral density and risk of breast cancer in older women. The study of osteoporotic fractures
25. Molecular basis of agonism and antagonism in estrogen receptor
26. Effect of raloxifene on serum lipids and coagulation factor in healthy postmenopausal women
27. Effect of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women
28. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
29. Acquired tamoxifen resistance: Correlation with reduced breast tumour levels of tamoxifen and isomerization of trans-4-hydroxy-tamoxifen
30. Development of tamoxifen-stimulated growth of MCF-7 tumour in athymic mice after-long antiestrogen administration
31. Chemoprevention of breast cancer with tamoxifen
32. Migration pattern and breast cancer risk in Asian-American women
33. Role of dietary fat in the causation of breast cancer: Point
34. Role of dietary fat in the causation of breast cancer: Counterpoint
35. Analysis of dietary fat, calories, body weight and the development of mammary tumours in rats and mice: A review
36. Genesis and growth of tumours III, effect of a high fat diet
37. Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer
38. Dietary fat and breast cancer
39. Design of the women's Health Initiative Clinical trial and Observational Study
40. Cohort studies of fat intake and the risk of breast cancer: A pooled analysis
41. Dietary factors and risk of breast cancer: Combined analysis of 12 case-control studies
42. Fat caloric intake and obesity: Lifestyle risk factors for breast cancer
43. Association of dietary intake of fat and fatty acids with risk of breast cancer
44. Dietary fat and cancer: Consistency of the epidemiologic data and disease prevention that may follow from a practical reduction in fat consumption
45. Diet, body size and breast cancer
46. Adiposity as a risk determinant for postmenopausal breast cancer
47. Association between energy balance and body mass index and risk of breast carcinoma in women from diverse racial and ethnic background in the US Cancer
48. Insulin and related factors in premenopausal breast cancer risk
49. Lower prevalence of breast cancer and cancer of the reproductive system among former college athletes compared to non-athletes
50. Alcoholic beverage consumption in relation to risk of breast cancer
51. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes
52. Prophylactic mastectomy - The price of fear
53. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
54. Does alcohol consumption increase the risk of breast cancer?
55. Cigarette smoking and urinary estrogens
56. Cigarette smoking and the level of adrenal androgen in postmenopausal women
57. Cigarette smoking and age at natural menopause
58. Future prospects for the prevention and cure of breast cancer
59. Cigarette smoking and risk of fatal breast cancer
60. Dietary carotenoids and vitamin A, C, and E and risk of breast cancer
61. Retinoic acid receptor β mediates the growth inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells
62. Inhibition of insulin and insulin like growth factor-1-stimulated growth of human breast cancer by 1,25 dihydroxyvitamin D3 and the vitamin D3 analogue EB 1089
63. Western nutrition and the insulin resistance syndrome: A link to breast cancer
64. Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer
65. A randomised trial of fenretinide in HRT users using IGF-1 as a surrogate biomarker
66. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
67. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin
68. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy
69. Breast cancer and hormonal contraceptive: Further results
70. Increased risk of breast cancer after low-dose irradiation
71. Radiation-induced breast cancer: Long term follow up of radiation therapy for benign breast disease
72. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
73. Risk of cancer in BRCA1 mutation carriers
74. Cancer risks in BRCA2 mutation carriers
75. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
76. Interest in genetic testing among first-degree relatives of breast cancer patients
77. Decision-making about genetic testing among women at familial risk for breast cancer
78. Presymptomatic DNA testing and prophylactic surgery in families with BRCA1 and BRCA2 mutation
79. Should prophylactic surgery be used in women at risk of breast cancer?
80. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes
81. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
82. Survival and tumour characteristics of breast cancer patients with germline mutation of BRCA1
83. Prophylactic mastectomy - Deliverance or delusion?
84. Some anatomical considerations of subcutaneous mastectomy
85. Subcutaneous mastectomy data: Final statistical analysis
86. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
87. Primary breast cancer after prophylactic mastectomy
88. Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy
89. Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies
90. Cancer of the breast after prophylactic subcutaneous mastectomy
91. Failure of subcutaneous mastectomy to prevent the development of breast cancer
92. Decision analysis effect of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutation
93. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive and BRCA2-positive patients
94. Bilateral prophylactic mastectomy in BRCA1/2 carriers
95. Prophylactic surgery in BRCA1/2 mutation carriers: Predictive factors and follow-up
96. A descriptive study of BRCA1 testing and reactions to disclosure of test result
97. An update on DNA-based BRCA1/BRCA2 genetic counselling in hereditary breast cancer
98. Prediction of and satisfaction with bilateral prophylactic mastectomy
99. Does prophylactic mastectomy in women at high risk for breast cancer provide a psychological benefit?
100. Sequence analysis of BRCA1 and BRCA2: Correlation of mutation with family history and ovarian cancer risk
101. Bilateral carcinoma of the breast
102. Survival of first and second primary breast cancer
103. Breast cancer linkage consortium and the risks of cancer in BRCA1 mutation carriers
104. Breast cancer in relation to nursing and menopausal history
105. Efficacy and safety of two doses of the selective estrogen receptor modulator (Serm) Ly 353381 in locally advanced or metastatic breast cancer (LAMBC): A randomised double blind phase 2 study
106. Study of the biologic effect of the aromatase inhibitor letrozole in healthy postmenopausal women: Rationale for prevention
107. Anastrozole is superior to tamoxifen as a first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomised trial
108. Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
109. Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy
110. Genistein induces mutation of cultured human breast cancer cells and prevents tumour growth in nude mice
111. Soya food and breast cancer risk: A prospective study in Hiroshima and Nagasaki, Japan
112. Synergy of demethylation of histone deacetylase inhibition in the re-expression of genes silenced in cancer
113. Histone deacetylase inhibitors: Inducers of differentiation of apoptosis of transformed cells
114. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer
115. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression
116. Retinoids and demethylating agents - Looking for partner
117. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
118. Matrix metalloproteinases: Biologic activity and clinical implications
119. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo
120. Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions: A marker for precancerous disease?
121. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer
122. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
123. Prevention and therapy of mammary cancer by monoterpenes
124. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
125. Future prospects for the prevention and cure of breast cancer